此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

2026年7月8日 更新者:Daiichi Sankyo

A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

The primary purpose of the study is to assess the safety, tolerability, and anti-tumor activity of HER3-DXd and T-DXd in the combination dosing regimens in participants with hormone receptor positive, HER2-low or HER2-ultralow, unresectable, or metastatic breast cancer.

研究概览

研究类型

介入性

注册 (估计的)

220

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Key Inclusion Criteria:

  1. Pathologically documented breast cancer that meets the following:

    1. Unresectable or metastatic.
    2. HR+ based on testing performed locally. HR+ (estrogen receptor [ER] and/or progesterone receptor [PgR] positive [ER or PgR greater than equal to (≥)1 percent (%)] per American Society of Clinical Oncology [ASCO]/College of American Pathologists [CAP] 2020 guidelines) in the unresectable or metastatic setting.
    3. Assessed as HER2-low (defined as Immunohistochemistry (IHC)2+/In-situ hybridization (ISH)- or IHC1+) or HER2-ultralow (defined as IHC 0 with any membrane staining in greater than (>) 0 and lesser than equal to (≤)10% of the cancer cells) locally for Part 1 and centrally for Part 2. The HER2 result must be from a tumor sample obtained in the unresectable or metastatic setting.

      • For Dose Regimen Determination (Part 1), HER2 status used for eligibility assessment must be determined locally (according to applicable regulations) using the PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody (Ventana Medical Systems, Inc.). Additional HER2 testing will be performed locally and according to applicable regulations using the prescribed test during Screening only if prior results obtained with this test are not available for eligibility assessment.
      • For Dose Expansion (Part 2), HER2 testing will be performed prospectively at a central laboratory using the pretreatment tumor tissue sample.
  2. Provides a pretreatment tumor tissue sample that meets one of the following collection requirements:

    1. Tissue biopsy collected from ≥1 lesion not previously irradiated and performed since progression with the most recent systemic cancer therapy regimen and prior to signature of the Tissue Screening informed consent form (ICF) (ARCHIVAL PRETREATMENT sample).

      OR

    2. Newly obtained pretreatment tumor biopsy from ≥1 lesion not previously irradiated and amenable to sampling, after signature of the Tissue Screening ICF (FRESH PRETREATMENT sample).
  3. Documented radiologic disease progression as per investigator assessment per RECIST v1.1 criteria (during or after most recent treatment).
  4. Documented refractoriness to endocrine therapy, defined as disease progression on one or more line of endocrine therapy in the unresectable or metastatic setting and determined by the investigator that participant would no longer benefit from further treatment with endocrine therapy.
  5. Prior treatment with a Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor in any setting. Subsequent endocrine therapies administered after progression on CDK4/6 inhibitor are allowed.
  6. Participants with genomic alterations/mutations (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha (PIK3CA), phosphatase and tensin homolog (PTEN), AKT, or Breast Cancer gene (BRCA)1/2) who are eligible for approved targeted therapies in combination with endocrine therapy or as monotherapy (according to local label and availability) must have received the corresponding therapy prior to enrollment, unless contraindicated or not accessible in their country/region.
  7. No prior chemotherapy for unresectable or metastatic breast cancer. Participants who have received chemotherapy in the neoadjuvant or adjuvant setting are eligible.
  8. ECOG performance status 0 or 1 at the time of Screening.
  9. Has ≥1 measurable lesion on CT or MRI per RECIST v1.1 by investigator assessment.
  10. Has adequate bone marrow reserve and organ function based on local laboratory data within 7 days prior to the first dose as specified in the protocol.

Key Exclusion Criteria:

  1. Prior treatment with an anti-HER3 antibody and/or antibody-drug conjugate (ADC) that consists of a topoisomerase I inhibitor (e.g., T-DXd) or any other topoisomerase I inhibitor therapy.
  2. Has any history of interstitial lung disease (ILD)/pneumonitis irrespective of steroid use, or current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at Screening. Examples of suspected ILD/pneumonitis by imaging include the presence of lung parenchymal fibrosis, such as CPFE, and any radiographic features consistent with ILA, including but not limited to, extensive ground glass opacities, reticular opacities, traction bronchiectasis, and honeycombing. Participants may be eligible if they had history of radiation pneumonitis that did not require steroids.
  3. Is receiving chronic systemic corticosteroids dosed at >10 mg prednisone daily or equivalent anti-inflammatory activity or any form of immunosuppressive therapy prior to randomization. Participants who require use of bronchodilators, inhaled or topical steroids, or local steroid injections may be included in the trial.
  4. Evidence of spinal cord compression or brain metastases, defined as being clinically active and symptomatic, or requiring therapy with corticosteroids or anticonvulsants to control associated symptoms. Participants with clinically inactive or treated brain metastases who are asymptomatic (i.e., without neurologic signs or symptoms and do not require treatment with corticosteroids or anticonvulsants) may be included in the trial but must have a stable neurologic status for ≥4 weeks prior to Cycle 1 Day 1. Participants with asymptomatic brain metastases and treated with anticonvulsants as prophylaxis can enroll.
  5. Inadequate washout period of prior treatment before randomization:

    1. Whole brain radiation therapy less than (<)28 days.
    2. Monoclonal antibodies other than immune checkpoint inhibitors, such as anti-vascular endothelial growth factor (VEGF) (e.g., bevacizumab) and anti-epidermal growth factor receptor (EGFR) (e.g., cetuximab) < 28 days.
    3. Immune checkpoint inhibitor therapy <21 days.
    4. Major surgery (excluding placement of vascular access) <28 days.
    5. Radiotherapy treatment to more than 30% of the bone marrow or wide field radiation or palliative stereotactic radiation to chest <28 days or palliative stereotactic radiation therapy to other anatomic areas <14 days.
    6. Chloroquine or hydroxychloroquine ≤14 days.
    7. Hormonal therapy <21 days prior to first dose of HER3-DXd.
    8. Live or live attenuated virus vaccination <30 days.
  6. Uncontrolled or significant cardiovascular disease, including any of the following:

    1. QTcF prolongation interval >450 milliseconds (ms) (average of triplicate determinations at screening).
    2. Left ventricular ejection fraction (LVEF) ≤50%.
    3. Resting systolic blood pressure >160 millimeters of mercury (mmHg) or diastolic blood pressure >100 mmHg.
    4. Myocardial infarction within 6 months.
    5. New York Heart Association (NYHA) Classes 3 or 4 congestive heart failure.
    6. Uncontrolled angina pectoris within 6 months.
    7. Cardiac arrhythmia requiring ongoing antiarrhythmic treatment.
    8. Diagnosed or suspected long QT syndrome or known family history of long QT syndrome.
    9. History of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
    10. Bradycardia of <50 beats per minute (bpm) unless the participant has a pacemaker.
    11. History of second- or third-degree heart block. Participants with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
    12. Coronary/peripheral artery bypass graft within 6 months.
    13. Complete left bundle branch block.
  7. Has history of other active malignancy within 3 years prior to randomization, except the following:

    1. Adequately resected nonmelanoma skin cancer.
    2. Adequately treated intraepithelial carcinoma of the cervix.
    3. Any other curatively treated in situ disease.
    4. Prostate carcinoma with a prostate-specific antigen value <0.2 nanograms per milliliter (ng/mL).
  8. Has unresolved toxicities from previous anticancer therapy, defined as toxicities (other than alopecia) not yet resolved to National Cancer Institute-Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0) Grade ≤1 or baseline.
  9. Any known contraindication to treatment, including hypersensitivity to either the drug substances or inactive ingredients in the drug products.

Note: Other protocol specified inclusion/exclusion criteria may apply.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Part 1: Arm 1: Dose Regimen Determination
Participants with unresectable or metastatic breast cancer (mBC) will receive T-DXd and HER3-DXd in combination regimen A until disease progression, death, unacceptable toxicity, or trial close.
Intravenous administration as determined by treatment arm.
其他名称:
  • HER3-DXd
  • U31402
Intravenous administration as determined by treatment arm.
其他名称:
  • T-DXd
  • DS8201a
实验性的:Part 1: Arm 2: Dose Regimen Determination
Participants with unresectable or mBC will receive T-DXd and HER3-DXd in combination regimen B until disease progression, death, unacceptable toxicity, or trial close.
Intravenous administration as determined by treatment arm.
其他名称:
  • HER3-DXd
  • U31402
Intravenous administration as determined by treatment arm.
其他名称:
  • T-DXd
  • DS8201a
实验性的:Part 2: Arm 3: Dose Expansion
Participants with unresectable or mBC will receive T-DXd and HER3-DXd in a combination regimen based on the available Part 1 data until disease progression, death, unacceptable toxicity, or trial close.
Intravenous administration as determined by treatment arm.
其他名称:
  • HER3-DXd
  • U31402
Intravenous administration as determined by treatment arm.
其他名称:
  • T-DXd
  • DS8201a
有源比较器:Part 2: Arm 4: Monotherapy
Participants with unresectable or mBC will receive T-DXd monotherapy until disease progression, death, unacceptable toxicity, or trial close.
Intravenous administration as determined by treatment arm.
其他名称:
  • T-DXd
  • DS8201a

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Part 1: Number of Participants With at Least One Treatment-emergent Adverse Event (TEAE) and Serious Adverse Event (SAE)
大体时间:Up to approximately 4.5 years
Adverse event(AE): any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).
Up to approximately 4.5 years
Part 2: Objective Response Per Response Evaluation Criteria in Solid Tumours Version 1.1 (RECIST v.1.1) as Assessed by the Investigator
大体时间:Up to approximately 4.5 years
Objective response is defined as participants with a best overall response (BOR) of confirmed complete response (CR) or confirmed partial response (PR), as assessed by investigator per RECIST v1.1.
Up to approximately 4.5 years

次要结果测量

结果测量
措施说明
大体时间
Part 1: Objective Response Per RECIST v.1.1 as Assessed by the Investigator
大体时间:Up to approximately 6 years
Objective response is defined as participants with a BOR of confirmed CR or confirmed PR, as assessed by investigator per RECIST v1.1.
Up to approximately 6 years
Part 2: Number of Participants With at Least One TEAE and SAE
大体时间:Up to approximately 6 years
AE: any untoward medical occurrence in a participant administered pharmaceutical product (PP) and which does not necessarily have a causal relationship with the treatment.AE can therefore be any unfavorable and unintended sign(including an abnormal laboratory finding, for example),symptom,or disease temporally associated with the use of PP, whether or not considered related to the PP.Pre-existing conditions which worsen during study are also considered as AEs.SAE:any AE that fulfilled any of following criteria:fatal,life-threatening,required inpatient hospitalisation or prolongation of existing hospitalization,resulted in persistent or significant disability/incapacity,was congenital anomaly/birth defect, medically significant or required intervention to prevent any of the other outcomes listed here. TEAEs:AEs with start or worsening date during the on-treatment period(from 1st dose date of trial intervention to 47 days after the last dose date of trial intervention).
Up to approximately 6 years
Parts 1 and 2: Disease Control Per RECIST v.1.1 as Assessed by the Investigator
大体时间:Up to approximately 6 years
Disease control is defined as participants with a BOR of confirmed CR, confirmed PR, or SD per RECIST v1.1.
Up to approximately 6 years
Parts 1 and 2: Duration of Response (DoR) Per RECIST v.1.1 as Assessed by the Investigator
大体时间:Up to approximately 6 years
DoR is defined as the time (month) from date of initial response (CR or PR) to the earlier date of the first objective documentation of radiographic disease progression or death due to any cause.
Up to approximately 6 years
Parts 1 and 2: Clinical Benefit Per RECIST v.1.1 as Assessed by Investigator
大体时间:Up to approximately 6 years
Clinical benefit is defined as participants with a BOR of confirmed CR, confirmed PR, or SD lasting ≥183 days, per RECIST v1.1.
Up to approximately 6 years
Parts 1 and 2: Progression-free Survival (PFS) Per RECIST v.1.1 as Assessed by Investigator
大体时间:Up to approximately 6 years
PFS by investigator is defined as the time (month) from the date of randomization to the earlier date of the first objective documentation of radiographic disease progression as assessed by investigator per RECIST v1.1 or death due to any cause.
Up to approximately 6 years
Parts 1 and 2: Time to Response (TTR) Per RECIST v.1.1 as Assessed by Investigator
大体时间:Up to approximately 6 years
TTR is defined as the time (months) from the start date of study treatment to the date of the first documentation of response (CR or PR). TTR will be calculated for responders only.
Up to approximately 6 years
Parts 1 and 2: Overall Survival (OS)
大体时间:Up to approximately 6 years
OS is defined as the time (month) from the date of randomization to the date of death due to any cause.
Up to approximately 6 years
Part 1: Maximum Serum Concentration (Cmax) of Anti-HER3 Antibody Conjugate Deruxtecan (HER3-ac-DXd)
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Total Anti-HER3 Antibody Liquid Chromatography-mass Spectrometry (LC-MS)
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of T-DXd
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Total Anti-HER2 Antibody
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Cmax of Released Payload (DXd)
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Trough Serum Concentration (Ctrough) of Anti-HER3-ac-DXd
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Total Anti-HER3 antibody LC-MS
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of T-DXd
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Total Anti-HER2 Antibody
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Ctrough of Released Payload (DXd)
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Time to Reach Maximum Serum Concentration (Tmax) of Anti-HER3-ac-DXd
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Total Anti-HER3 Antibody LC-MS
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of T-DXd
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Total Anti-HER2 Antibody
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 1: Tmax of Released Payload (DXd)
大体时间:Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Pre-dose and post-dose at multiple timepoints during each cycle, up to approximately 6 years (Cycle length=21 days)
Part 2: Correlation Between HER3 Protein Expression and Efficacy
大体时间:Up to approximately 6 years
HER3 protein expression in tumor tissue as determined by immunohistochemistry (IHC) and correlation with ORR, DoR, and PFS.
Up to approximately 6 years
Part 2: Correlation Between HER2 Protein Expression and Efficacy
大体时间:Up to approximately 6 years
HER2 protein expression in tumor tissue as determined by IHC and correlation with ORR, DoR, and PFS.
Up to approximately 6 years

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年8月3日

初级完成 (估计的)

2031年1月1日

研究完成 (估计的)

2032年5月1日

研究注册日期

首次提交

2026年7月8日

首先提交符合 QC 标准的

2026年7月8日

首次发布 (实际的)

2026年7月14日

研究记录更新

最后更新发布 (实际的)

2026年7月14日

上次提交的符合 QC 标准的更新

2026年7月8日

最后验证

2026年7月1日

更多信息

与本研究相关的术语

其他研究编号

  • U31402-287
  • 2024-517541-14-00 (克蒂斯)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

De-identified individual participant data (IPD) on completed studies and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 共享时间框架

Completed studies that has reached a global end or completion with all data set collected and analyzed, and for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 共享访问标准

Formal request from qualified scientific and medical researchers on IPD and clinical study documents on completed clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅